Introduction {#Sec1}
============

Sodium channel blockers (SCBs) have played a central role in the pharmacological management of focal and generalized tonic--clonic seizures since phenytoin was first used as an antiepileptic drug (AED) in 1936 \[[@CR1]\]. In addition to phenytoin, AEDs that are primarily SCBs in their mechanism of action include lamotrigine (LTG), lacosamide, rufinamide, and the dibenzazepine carboxamide family of AEDs, comprising carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL) \[[@CR1]\]. Despite sharing a common mechanistic target---the voltage-gated sodium channel---SCBs differ in their specific mechanisms of action. For example, phenytoin, CBZ, and OXC are thought to block the fast inactivation of sodium channels, whereas lacosamide and ESL are thought to act on the slow inactivated state of sodium channels \[[@CR1]--[@CR3]\]. Such mechanistic variations may underlie the observed differences in efficacy of SCBs, and help to explain why SCBs may show additive effects when used in combination, compared with when used as single agents alone \[[@CR1]\]. Furthermore, SCBs differ markedly from each other in their tolerability/safety profiles, particularly in terms of their variable propensity for enzyme induction \[[@CR1], [@CR4]\].

The objective of this article is to review current evidence for differences in effectiveness and tolerability between ESL and other agents within the dibenzazepine family of AEDs, and to discuss the implications of these differences in clinical practice. This article is based on previously conducted studies. All procedures performed in studies conducted by the authors involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards; informed consent was obtained from all individual participants included in these studies. The article also contains studies with human participants or animals that were not performed by any of the authors.

Overview of the Dibenzazepine Family {#Sec2}
====================================

CBZ was discovered by chance in the 1950s \[[@CR5], [@CR6]\] and, over subsequent decades, became widely accepted as the first drug of choice for focal epilepsy \[[@CR7]\] and the standard comparator for European regulatory studies in newly diagnosed epilepsy \[[@CR1]\]. OXC, a keto analogue of CBZ \[[@CR8]\], was introduced in the 1980s, with the aim of improving the pharmacokinetic profile and tolerability of CBZ \[[@CR6]\]. In the 1990s, esters of its major metabolite were synthesized in order to provide further improvements in pharmacokinetics and tolerability, which resulted in the development of ESL \[[@CR6], [@CR9]\].

Pharmacology and Potential Clinical Correlates {#Sec3}
----------------------------------------------

CBZ, OXC, and ESL all have a dibenzazepine nucleus bearing the 5-carboxamide substitute, but ESL is structurally distinct from CBZ and OXC at the 10,11-position (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR10], [@CR11]\], resulting in differences in metabolism, pharmacokinetics, and pharmacodynamics (Table [1](#Tab1){ref-type="table"}) \[[@CR15]\]. Unlike CBZ, ESL is not metabolized to carbamazepine-10,11-epoxide, the metabolite which may play a major role in causing adverse effects, such as drowsiness, dizziness, and diplopia \[[@CR6], [@CR9], [@CR16], [@CR17]\]. CBZ's tolerability is further affected by its potent enzyme induction properties, which reduce the duration and action of many drugs \[[@CR4]\] and may additionally contribute to the development of comorbidities, including vascular disease, osteoporosis, and sexual dysfunction, via effects on enzymes involved in endogenous metabolic pathways \[[@CR4], [@CR18]\].Fig. 1Chemical structure and main metabolic pathways of CBZ, OXC, and ESL. CBZ carbamazepine, ESL eslicarbazepine acetate, OXC oxcarbazepine.Reprinted by permission from Springer Nature, Neurotherapeutics (Eslicarbazepine acetate (BIA 2-093)), Luis Almeida, Patrício Soares-da-Silva, 2007 Table 1Summary comparison of metabolism, pharmacokinetics, and pharmacodynamics of CBZ, OXC, and ESL \[[@CR3], [@CR11]--[@CR14]\]CBZOXCESLMetabolism RouteHepaticHepaticHepatic Primary biotransformation pathwayEpoxide biotransformation to CBZ 10,11-epoxideCytosolic reduction to 10-monohydroxy derivativeHydrolysis to (*S*)-licarbazepinePharmacokinetics Time to maximum plasma concentration12 h4.5 h2--3 h Time to steady state1--2 weeks2--3 days4--5 days Half-life of active metabolite6 h9.3 h20--24 hPharmacodynamics Main active metaboliteCBZ 10,11-epoxide10-Monohydroxy derivative^a^(*S*)-Licarbazepine Primary mechanism of actionFast inactivation of voltage-gated sodium channelsFast inactivation of voltage-gated sodium channelsSlow inactivation of voltage-gated sodium channels*CBZ* carbamazepine, *ESL* eslicarbazepine acetate, *OXC* oxcarbazepine^a^An enantiomeric mixture of (*S*)-licarbazepine and (*R*)-licarbazepine in a ratio of 4:1

ESL's metabolism also differs from that of OXC. OXC rapidly undergoes hydroxylation to an active 10-monohydroxy derivative, comprising an enantiomeric mixture of (*S*)-licarbazepine ("eslicarbazepine") and (*R*)-licarbazepine (in a ratio of 4:1), with a small amount of parent compound remaining in the plasma \[[@CR8], [@CR11], [@CR19]\]. ESL is stereoselectively metabolized primarily to (*S*)-licarbazepine, which accounts for approximately 94% of plasma drug exposure following oral administration of ESL, with (*R*)-licarbazepine and oxcarbazepine accounting for approximately 5% and less than 1%, respectively (ratio of (*S*)-licarbazepine to (*R*)-licarbazepine, approximately 19:1; Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11], [@CR19]\]. Importantly, this stereoselective metabolism of ESL avoids the early peaks in (*R*)-licarbazepine and OXC concentrations observed in plasma and cerebrospinal fluid following immediate-release OXC administration, which are thought to be associated with OXC-related side effects, such as dizziness and headache \[[@CR19]\]. Consequently, ESL may be associated with fewer neurological/psychiatric side effects than OXC \[[@CR13], [@CR14], [@CR20]\].

Evidence from therapeutic drug monitoring databases has demonstrated that ESL is associated with fewer interactions with other AEDs than CBZ and OXC \[[@CR21]\]. The pharmacokinetic profile of ESL was shown to be unaffected by enzyme-inducing AEDs and valproate, and ESL did not affect the metabolism of LTG; by contrast, CBZ clearance was found to be increased by enzyme-inducing AEDs and valproate, and LTG clearance was increased by both OXC and CBZ \[[@CR21]\]. Furthermore, once-daily dosing of ESL may improve the likelihood of adherence to ESL treatment in comparison with CBZ and OXC, since adherence to a once-daily AED dosing regimen has been shown to be significantly better than to a twice- or three-times daily dosing regimen \[[@CR22]\].

Pharmacodynamic Differences {#Sec4}
---------------------------

ESL differs pharmacodynamically from CBZ, since ESL is thought to act primarily by enhancing the slow inactivation of voltage-gated sodium channels, whereas CBZ is thought to alter the fast inactivation of these channels \[[@CR3]\]. As previously mentioned, although OXC and ESL share a common active metabolite (eslicarbazepine), this accounts almost exclusively for ESL's pharmacodynamic effect, whereas it is the monohydroxy derivative of OXC (comprising a substantial proportion of (*R*)-licarbazepine as well as eslicarbazepine) that accounts for its pharmacodynamic effect (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR11], [@CR19]\]. The apparent affinity of eslicarbazepine for voltage-gated sodium channels in the inactivated and resting states is considerably lower than that of CBZ and (*R*)-licarbazepine, suggesting that eslicarbazepine has enhanced selectivity for inhibiting rapidly firing active "epileptic" neurons \[[@CR23]--[@CR26]\]. This may in part explain the observed efficacy of ESL in the presence of CBZ resistance in experimental models of epilepsy, which have demonstrated significant add-on effects when ESL is used in combination with CBZ \[[@CR27], [@CR28]\]. These pharmacodynamic differences are thought to influence the clinical effectiveness and tolerability of the members of the dibenzazepine family, CBZ, OXC, and ESL.

Differences in Effectiveness: Evidence from Clinical Studies {#Sec5}
============================================================

Few clinical studies have directly compared the efficacy and tolerability of members of the dibenzazepine family. Results from the Standard And New Antiepileptic Drugs (SANAD) study suggested a non-significant advantage for CBZ compared with OXC \[[@CR7]\]. ESL was not included as it was not approved at the time SANAD was conducted. In a phase III randomized controlled trial, ESL was shown to be non-inferior to controlled-release CBZ (CBZ-CR) as monotherapy for patients with newly diagnosed focal epilepsy \[[@CR29]\]. Seizure freedom rates during the entire 6-month evaluation period for the per protocol population (the primary endpoint of the trial) were 71.1% with ESL and 75.6% with CBZ-CR \[[@CR29]\].

Despite the lack of direct comparative data, evidence for potential differences in effectiveness (and tolerability) within the dibenzazepine family has emerged from studies in which patients have received adjunctive treatment with a dibenzazepine AED. These patients had achieved insufficient seizure control with another AED, or were transitioned from one dibenzazepine agent to another, because of lack of effectiveness or poor tolerability. The majority of this evidence---as outlined below---has emerged from the real-world setting, highlighting the importance of clinical practice studies in further complementing evidence obtained from clinical trials.

A post hoc analysis was conducted of 1049 patients enrolled in three phase III, multicenter, double-blind, randomized, placebo-controlled trials, in which adults with focal seizures, despite treatment with one to three AEDs, received adjunctive treatment with ESL \[[@CR30]\]. Efficacy was compared between patients who did (*n* = 611) and did not (*n* = 438) receive CBZ as a concomitant AED \[[@CR30]\]. Seizure frequency over a 12-week maintenance period (the primary endpoint) was significantly reduced, compared with placebo, in patients treated with ESL 800 and 1200 mg/day, not only when administered without CBZ (*p* \< 0.01 and *p* \< 0.05, respectively) but, interestingly, also when administered with CBZ (*p* \< 0.01 and *p* \< 0.0001, respectively) \[[@CR30]\]. In patients not receiving CBZ, responder rates (response defined as at least 50% seizure frequency reduction) were 26% with placebo, 39% with ESL 800 mg/day, and 40% with 1200 mg/day (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR30]\]. In those receiving CBZ, responder rates were 19% with placebo, 34% with ESL 800 mg/day and 47% with ESL 1200 mg/day (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR30]\]. These data suggest that ESL was efficacious in both subsets of patients, with or without concomitant CBZ. Patients who did not achieve seizure control with CBZ may still benefit from either switching to or adding in adjunctive ESL.Fig. 2Responder rates in patients included in the ESL phase III adjunctive therapy trials who were not receiving CBZ or who were receiving CBZ. Response was defined as at least 50% seizure frequency reduction from baseline \[[@CR30]\]. CBZ carbamazepine, ESL eslicarbazepine acetate

These findings are supported by the results of real-world clinical practice studies. The ESLIBASE study was a 1-year, multicenter, retrospective, non-interventional study, which evaluated the long-term efficacy and safety of adjunctive ESL therapy in 327 patients with focal epilepsy in a clinical practice setting in Spain \[[@CR31]\]. Sixty patients included in the ESLIBASE study were being treated with CBZ at the start of the study \[[@CR31]\]. Of these, 45 were transitioned from CBZ to ESL (because of lack of efficacy \[*n* = 28\] and tolerability problems \[*n* = 17\] with CBZ; CBZ to ESL ratio, 1:1.5) and 15 were treated with both AEDs \[[@CR31]\]. Among those who transitioned from CBZ to ESL (*n* = 45), 13.3% were seizure free during the 3 months prior to inclusion \[[@CR31]\]. After 12 months of ESL treatment, 11.4% of patients were seizure free, 38.7% had responded to ESL treatment (response defined as at least 50% seizure frequency reduction from baseline), and 20.0% had experienced worsening of seizures \[[@CR31]\]. Similarly, 50 patients were receiving OXC before the start of the study, of whom 48 were transitioned to ESL (because of adverse events \[AEs; *n* = 26\] and lack of efficacy \[*n* = 22\]; OXC to ESL ratio, 1:1) and two were treated with both AEDs. Among patients who transitioned from OXC to ESL (*n* = 48), 16.7% were seizure free in the 3 months prior to inclusion \[[@CR31]\]. After 12 months of ESL treatment, 31.3% were seizure free, 45.9% were responders, and 16.7% had experienced worsening of seizures \[[@CR31]\].

A single-center, observational, descriptive, cross-sectional study investigated the effectiveness and safety/tolerability of ESL in 61 consecutive patients with drug-resistant epilepsy over a mean follow-up duration of 4.7 months \[[@CR32]\]. These included 13 patients who transitioned overnight from CBZ to ESL (CBZ to ESL ratio, 1:1 to 1:1.3; up to a maximum ESL dose of 1600 mg/day) and 12 patients who transitioned overnight from OXC to ESL (OXC to ESL ratio, 1:1.1) \[[@CR32]\]. Eight of the 13 patients who transitioned from CBZ were followed up for more than 3 months after initiating ESL and the median number of seizures/month increased by 33.3% in these patients (*p* = not significant) \[[@CR32]\]. In contrast, 11 of the 12 patients who transitioned from OXC were followed up for more than 3 months and the median number of seizures/month decreased by 66.7% in these patients (*p* = 0.017) \[[@CR32]\].

The EARLY-ESLI study was a multicenter, retrospective, 1-year, observational study conducted in 16 hospitals in Spain, which included 253 patients with focal epilepsy, aged 18 years or over, in whom ESL treatment was initiated because of failure with the first AED monotherapy \[[@CR33]\]. The primary reasons for ESL initiation were lack of efficacy (*n* = 157) and tolerability problems (*n* = 74) with the first AED monotherapy \[[@CR33]\]. A total of 28 patients converted from CBZ monotherapy to ESL monotherapy at some point during follow-up. Three of four patients who converted to ESL because of lack of efficacy with CBZ were seizure free at 1 year \[[@CR33]\]. Similarly, 12 patients converted from OXC monotherapy to ESL monotherapy, and one of four patients who did so because of lack of efficacy was seizure free at 1 year \[[@CR33]\].

Differences in Effectiveness: Summary {#Sec6}
-------------------------------------

Despite limited direct head-to-head data, ESL has been shown to be effective as adjunctive therapy in patients who have previously achieved inadequate seizure control with CBZ \[[@CR30]\]. This indicates that the use of different dibenzazepine agents in combination can provide additive effectiveness benefits, which may reflect underlying differences in the mechanisms of action of this family of AEDs \[[@CR1], [@CR27], [@CR28]\]. Similarly, this may in part explain why ESL monotherapy can be effective in patients who have switched from another dibenzazepine, such as CBZ or OXC, because of inadequate efficacy \[[@CR31]--[@CR33]\]. Overall, the evidence outlined here demonstrates that patients who have not achieved adequate seizure control with CBZ or OXC may experience improvement in seizure control with ESL, when used either as an adjunctive treatment or as monotherapy.

Tolerability Profiles: Do These Differ? {#Sec7}
=======================================

In the phase III trial that compared ESL with CBZ-CR as monotherapy for patients with newly diagnosed focal epilepsy, the safety profile of ESL was generally similar to that of CBZ-CR \[[@CR29]\]. The incidence of treatment-emergent AEs judged to be at least possibly treatment-related was lower with ESL than with CBZ-CR (42.1% vs 51.5%), as was the incidence of treatment-emergent AEs leading to discontinuation (14.0% vs 18.4%) \[[@CR29]\]. Fewer patients treated with ESL versus CBZ-CR experienced treatment-related increases in gamma-glutamyl transferase (3.5% vs 13.1%) and alanine aminotransferase (0.5% vs 2.2%) \[[@CR29]\]. In addition, fewer patients treated with ESL versus CBZ-CR discontinued because of allergic dermatitis (0.5% vs 1.7%) \[[@CR29]\]. The incidence of hyponatremia judged to be at least possibly treatment-related was higher with ESL than with CBZ-CR (2.5% vs 1.0%), but only one patient (in the CBZ-CR group) discontinued because of this AE \[[@CR29]\]. In the post hoc analysis of 1049 patients enrolled in three ESL phase III adjunctive therapy trials, in which outcomes were compared between patients who did (*n* = 611) and did not (*n* = 438) receive CBZ as a concomitant AED, the incidence of treatment-emergent AEs was higher in patients treated with CBZ (50% with placebo; 71% with ESL) than in those who were not treated with CBZ (40% with placebo; 55% with ESL) \[[@CR30]\].

Several real-world clinical practice studies have investigated the impact on tolerability of transitioning patients who were experiencing OXC- or CBZ-related AEs to ESL \[[@CR31]--[@CR37]\]. In a single-center, retrospective chart review of 23 patients with focal epilepsy who were transitioned overnight from OXC to ESL because of tolerability problems, an evaluation of the effects of the transition was made after 1 and 3 months of ESL treatment \[[@CR34]\]. The most intolerable OXC-related AEs were somnolence, dizziness, and diplopia \[[@CR34]\], consistent with the aforementioned pattern of OXC metabolism \[[@CR19]\]. OXC-related AEs had resolved in 14/23 (60.9%) and 15/23 (65.2%) patients 1 and 3 months after transition, respectively \[[@CR34]\]. Two-thirds (66.5%) of OXC-related AEs occurred in the morning and 93.4% of these resolved after transitioning from OXC to ESL \[[@CR34]\]. The only ESL-related AE reported by at least 10% of patients was headache, and, importantly, all patients continued ESL treatment throughout the study period \[[@CR34]\].

A retrospective, single-center study was conducted in which 21 patients with drug-resistant focal epilepsy on a stable dose of immediate-release OXC for at least 4 weeks were transitioned overnight to ESL because they experienced persistent seizures with OXC but were unable to tolerate increased OXC dosing because of AEs \[[@CR35]\]. Tolerability (assessed using the Adverse Events Profile \[AEP\]), quality of life (assessed using the Quality of Life in Epilepsy Inventory-10 \[QOLIE-10\]), and alertness (assessed as reaction time using a subtest of the Test Battery for Attention Performance version 2.3) were compared immediately before and 5 days after transitioning from OXC to ESL \[[@CR35]\]. Following transition to ESL, there were significant improvements in mean scores for AEP (*p* \< 0.001), QOLIE-10 (*p* = 0.001), and alertness (*p* \< 0.05) \[[@CR35]\]. Overall, AEP total scores, QOLIE-10 total scores, and alertness scores improved for 100.0%, 81.0%, and 76.2% of patients, respectively \[[@CR35]\]. Serum sodium levels (measured on days 0 and 5) remained stable, indicating that the likelihood of developing hyponatremia did not increase after switching treatment overnight \[[@CR35]\].

In a single-center, observational, descriptive, cross-sectional study of 61 consecutive patients with drug-resistant epilepsy who were treated with ESL over a mean follow-up duration of 4.7 months, eight of 13 patients who were transitioned overnight from CBZ to ESL experienced AEs, as did four of 12 patients who transitioned overnight from OXC to ESL, but all AEs were transient \[[@CR32]\]. Two patients who transitioned from OXC to ESL reported that the AEs they experienced with OXC (dizziness and drowsiness) improved after transitioning to ESL \[[@CR32]\]. Overall, decreased sodium levels were observed in 4/61 (6.6%) patients, none of whom was taking OXC or CBZ \[[@CR32]\]. None of these sodium values were below 125 mmol/L \[[@CR32]\]. In addition, hyponatremia resolved (from 128 to 138 mmol/L) in one patient and remained the same (133 mmol/L) in another patient after transitioning from OXC to ESL \[[@CR32]\]. In a multicenter, retrospective case series of 29 elderly patients (\> 65 years) with focal seizures who were treated with ESL, the tolerability profile improved in four of five patients who transitioned from CBZ or OXC to ESL because of AEs \[[@CR36]\]. Overall, 3/29 (10.3%) patients developed hyponatremia, but only one developed symptoms (confusion) that resolved after withdrawal of ESL \[[@CR36]\].

In the EARLY-ESLI study, 14 patients converted from CBZ monotherapy to ESL monotherapy because of tolerability problems with CBZ, and only two of these patients reported AEs at 1 year \[[@CR33]\]. In addition, of the five patients converted from OXC monotherapy to ESL monotherapy because of tolerability problems with OXC, three had no AEs with ESL at 1 year \[[@CR33]\]. A total of 137 patients withdrew to ESL monotherapy from treatment with other AEDs during EARLY-ESLI, of whom three (2.2%) developed hyponatremia; hyponatremia was symptomatic in only one of these patients (113 mEq/L) \[[@CR33]\]. In the ESLIBASE study, the study population included 26 patients who were transitioned to ESL from OXC because of OXC-related AEs and 17 patients who transitioned from CBZ because of CBZ-related AEs \[[@CR31]\]. Overall, 15/26 (57.7%) patients previously treated with OXC no longer had AEs after transitioning to ESL, and 8/17 (47.1%) previously treated with CBZ no longer had AEs after transitioning to ESL \[[@CR31]\]. Thus, after transition from either OXC or CBZ to ESL, approximately 50% of patients no longer experienced AEs. In the overall ESLIBASE population, hyponatremia (ranging from 116 to 128 mEq/L) was reported in 9/327 (2.8%) patients and led to treatment discontinuation in four patients \[[@CR31]\]. Hyponatremia was asymptomatic in eight patients; the remaining patient reported confusion that resolved rapidly after ESL discontinuation and did not require hospital admission \[[@CR31]\].

Nonadherence to AEDs is a common and challenging problem in epilepsy, with nonadherence rates of up to 60% reported in some populations \[[@CR37]\]. In the EARLY-ESLI study, adherence improved in all of the 10 patients who converted from CBZ to ESL monotherapy because of adherence problems with CBZ \[[@CR33]\]. Similarly, of five patients who converted from OXC monotherapy to ESL monotherapy because of tolerability problems with OXC, three had no AEs with ESL at 1 year, and of three patients who converted because of adherence problems with OXC, two had no adherence problems with ESL at 1 year \[[@CR33]\].

Differences Within the Dibenzazepine Family in Their Impact on Lipid Markers {#Sec8}
----------------------------------------------------------------------------

Treatment with enzyme-inducing AEDs, including CBZ, has been associated with increased serum lipid levels \[[@CR4]\]. Although (*S*)-licarbazepine is a weak inducer of cytochrome P450 3A4 and uridine 5′-diphospho-glucuronosyltransferase \[[@CR14]\], it is a less potent enzyme inducer than CBZ, which induces a broader range of oxidative and conjugating enzymes \[[@CR1]\]. Lipid profiles are particularly relevant in light of epidemiological evidence demonstrating that patients with epilepsy have significantly elevated rates of cardiovascular and cerebrovascular disease \[[@CR4]\]. In a study in which 12 patients with epilepsy transitioned from CBZ to OXC, cytochrome P450 enzyme system function (assessed by evaluating antipyrine pharmacokinetics) was shown to normalize after 2 months, resulting in a significant reduction in serum total cholesterol levels and a detectable but not statistically significant reduction in low-density lipoprotein cholesterol levels (*p* = 0.057), with serum concentrations of high-density lipoprotein cholesterol and triglycerides remaining unchanged \[[@CR38]\]. Seizure control was generally similar following the transition from CBZ to OXC, with only one patient experiencing an increase in seizure frequency \[[@CR38]\]. Two further studies have specifically investigated the impact of ESL on patients' lipid profiles, including the effect of transitioning from CBZ or OXC to ESL \[[@CR39], [@CR40]\]. A retrospective cohort study of 36 adult patients assessed lipid levels before and after initiating ESL as adjunctive therapy over an average follow-up of 11 months \[[@CR39]\]. After at least 6 months of ESL treatment, there were significant reductions in the levels of total cholesterol (from 191.3 to 179.7 mg/dL; *p* \< 0.0001) and low-density lipoprotein cholesterol (from 114.6 to 103.1 mg/dL; *p* \< 0.0001), and a significant increase in the level of high-density lipoprotein cholesterol (from 57.5 to 63.9 mg/dL; *p* \< 0.0001) \[[@CR39]\]. A second observational, retrospective, single-center, cohort study investigated the impact of ESL treatment on the lipid profiles of 108 patients over a median duration of 23.1 months (range 3--41 months) \[[@CR40]\]. Of these, 51.9% had switched to ESL from prior treatment with CBZ or OXC \[[@CR40]\]. In the overall population, mean total cholesterol levels decreased significantly from previous pathological (\> 200 mg/dL) to normal (\< 200 mg/dL) values during ESL treatment (*p* = 0.015) \[[@CR40]\]. In the subgroup of patients who transitioned from CBZ or OXC to ESL, there was a significant decrease in median triglyceride levels (*p* \< 0.001) and mean low-density lipoprotein cholesterol (*p* = 0.014), and a marked decrease in mean total cholesterol (*p* = 0.053) \[[@CR40]\]. The proportion of patients with hypercholesterolemia also decreased significantly after transitioning to ESL (from 57.1% to 37.5%; *p* = 0.018), as did the proportion of patients with hypertriglyceridemia (from 10.8% to 1.8%; *p* = 0.011) (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR40]\]. Both studies therefore suggest that switching to ESL is of value when considering lipid profiles.Fig. 3Percentage of patients with normal or elevated levels of total cholesterol and triglycerides before and after switching treatment from CBZ or OXC to ESL. CBZ carbamazepine, ESL eslicarbazepine acetate, OXC oxcarbazepine.Adapted from Epilepsy Research, 115, M. Ley, A. Principe, J. Jiménez-Conde, R. Rocamora, Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests, pp. 147--152, Copyright (2015), with permission from Elsevier

Tolerability Differences: Summary {#Sec9}
---------------------------------

In a phase III monotherapy trial, ESL was shown to have a generally similar tolerability profile to CBZ-CR, but with lower incidences of treatment-related AEs and AEs leading to discontinuation \[[@CR29]\]. In clinical trials of ESL adjunctive therapy, treatment regimens that included CBZ were shown to be less well tolerated than those that did not, despite attaining clinical efficacy \[[@CR30]\]. There is also considerable evidence to demonstrate that patients transitioning from OXC or CBZ to ESL because of AEs experience improvements in tolerability \[[@CR31]--[@CR36]\]. Interestingly, improvements in quality of life and/or alertness were also reported \[[@CR35]\]. Patients transitioning from OXC or CBZ to ESL have additionally demonstrated significant improvements in lipid profiles \[[@CR40]\]. Transitioning from CBZ or OXC to ESL does not appear to be associated with an increased likelihood of developing hyponatremia; however, it is good practice to monitor for the potential development of hyponatremia with all dibenzazepine agents, particularly in the elderly. Blood level monitoring is not routinely required for dibenzazepine AEDs \[[@CR12]--[@CR14]\]. However, decreased platelet or white blood cell counts may occur with CBZ treatment and it is therefore recommended that a complete blood count should be obtained before starting CBZ treatment and periodically thereafter \[[@CR12]\].

Clinical Implications {#Sec10}
=====================

ESL has been shown to be effective in patients who have previously not achieved adequate seizure control with CBZ or OXC, when used instead of these agents. ESL has also been shown to improve effectiveness when added to CBZ treatment. Such evidence is consistent with findings from experimental models that have revealed differences in the mechanism of action between dibenzazepine agents \[[@CR3], [@CR27], [@CR28]\], supporting the notion of "rational polytherapy", whereby agents with different mechanisms of action may synergize when used in combination to provide enhanced effectiveness \[[@CR41]\]. Rational polytherapy must, however, also take account of the increased risk of adverse effects and pharmacokinetic interactions as a patient's drug burden is increased, and thus balance the potential benefit of increased effectiveness with polytherapy against the potential risk of increased tolerability problems \[[@CR42]\]. The co-administration of more than one AED is likely to limit dosing of the newly added drug. In patients who fail first-line monotherapy, and have started their second monotherapy, there is evidence to support switching from CBZ or OXC to ESL. Evidence from clinical practice studies also demonstrates that there are differences in tolerability within the dibenzazepine family, since patients who have experienced CBZ- or OXC-related AEs may experience improvements in tolerability when transitioned to ESL. Furthermore, it may be appropriate to transition patients from CBZ to ESL if they are experiencing, or at risk of developing, metabolic problems resulting from CBZ induction of enzymes involved in endogenous metabolic pathways (e.g., hypercholesterolemia, osteoporosis, sexual dysfunction) \[[@CR4], [@CR43], [@CR44]\]. Published guidance has outlined the methodological considerations associated with transitioning patients from CBZ or OXC to ESL \[[@CR43], [@CR44]\]. Taken together, and despite the lack of direct comparative data, current evidence demonstrates that ESL differs from other dibenzazepine AEDs, highlighting the importance of adapting and tailoring treatment to each patient's specific needs.
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